Molecular Mechanisms of VEGF-A Action during Tissue Repair  by Eming, Sabine A. & Krieg, Thomas
Molecular Mechanisms of VEGF-A Action during
Tissue Repair
Sabine A. Eming1 and Thomas Krieg1
Vascular endothelial growth factor-A (VEGF-A) is a crucial mediator of vascular hyperpermeability, angiogenesis,
and inflammation, processes intimately involved in tissue repair. Although much emphasis has been placed on
understanding the synthesis and stability of VEGF-A mRNA, relatively little attention has been given to the study
of the stability and processing of VEGF-A proteins themselves. In recent years, several studies indicated that
VEGF-A protein activity is highly controlled through interaction with angiogenic or non-angiogenic mediators.
We analyzed mechanisms that might control extracellular VEGF-A processing during wound repair. First, our
studies provide evidence that VEGF-A protein is a target of proteases present in the microenvironment of
human chronic non-healing wounds. Serine proteases, in particular plasmin cleave VEGF165 and digested VEGF
fragments, showed decreased mitogenic activity. Inactivation of the plasmin cleavage site Arg110/Ala111
preserved the structural integrity and increased the angiogenic potency of VEGF165 when tested in an impaired
healing mouse model. Secondly, we identified significantly increased levels of the potent VEGF-A inhibitor, the
soluble form of the VEGF receptor VEGFR-1 (sVEGFR-1) in non-healing wounds when compared to healing
wounds. Wound closure in healing and non-healing wounds correlated significantly with a decline in sVEGFR-1
levels. These observations support the concept that VEGF-A and VEGF-A receptors are important mediators in
tissue repair. Further, our data provide mechanisms how VEGF-A-mediated interactions are disturbed during
impaired healing.
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VASCULAR ENDOTHELIAL GROWTH FACTOR-A
AND VASCULAR ENDOTHELIAL GROWTH FACTOR-A
RECEPTORS IN TISSUE HOMEOSTASIS AND REPAIR
Vascular endothelial growth factor-A (VEGF-A), the most
potent and specific vascular growth factor, is a key regulator
in physiological and pathological angiogenesis (Ferrara,
2004). VEGF-A levels are regulated through transcriptional
control and mRNA stability. Moreover, by differential mRNA
splicing, the single human VEGF-A gene gives rise to at least
eight isoforms (VEGF121, 145, 148, 162, 165, 183, 189, and
206) whose relative abundance varies among different tissues
(Tischer et al., 1991; Ferrara, 2004); the 165-amino-acid
isoform is the major gene product found in human tissues
(Figure 1). The domains encoded by exons 1–5 of the VEGF-A
gene are present in all VEGF splice variants and contain
information required for the recognition of the tyrosine kinase
VEGF receptors 1 (VEGFR-1/fms-like tyrosine kinase 1) and 2
(VEGFR-2/KDR/Flk-1) (Keyt et al., 1996a). The isoforms are
distinguished by the presence or absence of the peptides
encoded by exons 6 and 7 of the VEGF-A gene that code for
two independent heparin-binding domains. Substantial evi-
dence indicates that differences in the expression of the
heparin-binding domains are crucially involved in the diverse
biochemical and functional properties of the VEGF-A splice
forms, including binding to cell surfaces and extracellular
matrix (Park et al., 1993; Ortega et al., 1998; Carmeliet et al.,
1999; Hutchings et al., 2003), receptor binding character-
istics (Soker et al., 1998), endothelial cell adhesion and
survival (Dor et al., 2002; Hutchings et al., 2003), and
vascular branch formation (Ruhrberg et al., 2002) (Figure 1).
VEGF-A expression in normal skin is absent. However,
mechanical injury in skin provokes a strong upregulation of
VEGF-A expression, which correlates both temporally and
spatially with the proliferation of new blood vessels (Brown
et al., 1992) (Figure 2). In these initial studies, immuno-
histological and in situ hybridization analysis identified
epidermal keratinocytes and infiltrating macrophages as
the principal VEGF-A source during skin repair. Since then
in vitro analysis revealed that also platelets, neutrophils, and
mast cells are significant VEGF-A sources and might provide
additional VEGF-A sources during wound angiogenesis.
Wound healing studies in two different transgenic mouse
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VEGF-A-GFP reporter models gave contradictive results with
regard to the sites of VEGF-A expression during repair
(Fukumura et al., 1998; Kishimoto et al., 2000). Whereas
the model of Fukumura revealed VEGF-A expression pre-
dominantly in fibroblasts, Kishimoto showed primarily
epidermal VEGF-A expression. These opposing results are
most likely explained by the different promoter regions used.
Furthermore, positional effects of the transgene might explain
Figure 1. Exon structure and function of VEGF-A. Alternative splicing results in the generation of several isoforms of VEGF-A, which differ in the expression of
the heparin-binding domain; alternative expression of the heparin-binding domain results in different isoform functions.
Figure 2. Model of VEGF-A actions at the wound site. Following mechanical injury, VEGF-A expression is upregulated in epidermal keratinocytes at the wound
edges and infiltrating macrophages/neutrophils; induction of VEGF-A expression is regulated by hypoxia, proinflammatory cytokines, and growth factors;
VEGF-A released by keratinocytes and/or infiltrating inflammatory cells activate VEGF receptors in a paracrine manner. VEGF-A controls wound repair by
inducing vascular permeability, influx of inflammatory cells into the site of injury, angiogenesis through induction of endothelial cell-specific gene
expression, and potentially the recruitment of marrow-derived endothelial progenitor cells into the local wound site.
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differences in transgene expression. Thirdly, in both studies,
the human promoter was used which might be differentially
regulated in murine models.
VEGF-A transcription is regulated by numerous external
factors, including growth factors, proinflammatory cytokines,
hormones, and cellular stress (Pages and Pouyssegur, 2005).
One of the best-characterized factor of VEGF-A synthesis is
hypoxia. In vitro analysis indicates that beside hypoxia,
proinflammatory cytokines, and growth factors regulate
VEGF-A expression during repair (Detmar et al., 1995;
Frank et al., 1995).
VEGF-A action during repair is thought to regulate
different processes, including vascular permeability, the
influx of inflammatory cells into the site of injury, migration
and proliferation of pre-existing endothelial cells, and, as
suggested recently, the recruitment of marrow-derived
endothelial progenitor cells to the local wound site where
they are able to accelerate repair (Brown et al., 1992; Nissen
et al., 1998; Galiano et al., 2004). The first study that
indicated a crucial function for VEGF-A in tissue repair was
provided by Frank et al. (1995). In this study, it was shown
that in diabetic mice (db/db), which are significantly
compromised in wound healing, VEGF-A mRNA and
intracellular VEGF-A protein processing was dramatically
decreased during the repair process. Wound angiogenesis is
significantly impaired in these mice, thus providing a
causative link between decreased VEGF-A activity, impaired
wound angiogenesis, and delayed healing. Furthermore, the
role of VEGF-A in tissue repair was revealed in a study where
application of neutralizing antibodies caused a striking
reduction in wound angiogenesis, fluid accumulation, and
granulation tissue formation in a pig wound model (Howdie-
shell et al., 2001). In addition, the role of VEGF-A in tissue
repair has been demonstrated by the treatment of ischemic
wounds with VEGF-A protein, or adenovirus-mediated
VEGF165 gene transfer, which enhanced wound healing in
streptozotocin-induced diabetic mice (Corral et al., 1999;
Romano Di Peppe et al., 2002). Along these lines, recently,
we and others provided evidence that the db/db delayed
healing phenotype can be reversed by the local treatment of
wounds with VEGF165 protein, most likely by promoting
wound angiogenesis (Galiano et al., 2004; Roth et al., 2006).
Interestingly, transgenic mice overexpressing VEGF-A in the
epidermis showed no difference in wound closure rate when
compared to their wild-type littermates, illustrating the
importance of using an impaired healing model for testing
the effects of VEGF in tissue repair (Hong et al., 2004).
Recently, cell-specific ablation of VEGF-A expression in the
epidermis supported an important role of epidermal-derived
VEGF-A in wound closure (Rossiter et al., 2004). Together,
these data provide substantial evidence that VEGF-A activity
is a crucial regulator of wound repair.
VEGF-A exerts its biological effects upon binding to two
high-affinity receptor tyrosine kinases VEGFR-1 and VEGFR-
2, and the recently described neuropilin-1 receptor, all of
which are expressed predominantly but not exclusively on
endothelial cells (Figure 3) (Ferrara, 2004). Non-endothelial
cells that express VEGFRs and are known to be involved in
wound repair include macrophages, neutrophils, pericytes,
and stromal cells; whether VEGF signaling in these cells is
functionally relevant in tissue repair is currently unknown.
During skin repair, expression of VEGFR-1 and VEGFR-2 has
been shown to be upregulated primarily in dermal capillaries
and macrophages (Lauer et al., 2000; Zhang et al., 2004). In
vivo studies support the hypothesis that epidermally derived
VEGF can stimulate angiogenesis in a paracrine manner by
demonstrating increased microvascular density in the skin of
VEGF transgenic mice (Detmar et al., 1998). Whereas most of
endothelial VEGF-A signaling described to date is largely
mediated via VEGFR-2, the function of VEGFR-1 is less clear.
Strong experimental evidence indicates that VEGFR-1 on the
vasculature may act primarily as a ligand-binding molecule
during angiogenesis, rather than as a signaling tyrosine
kinase; in VEGFR-1 null mutant mice, the abnormal over-
growth of endothelial cells has been shown to be lethal. In
vitro studies revealed that VEGFR-1 on monocytes/macro-
phages promotes chemotaxis (Hiratsuka et al., 1998).
Interestingly, recent data indicate that VEGFR-1-mediated
function in wound repair is regulated in part by binding of
placental growth factor (PlGF), another ligand of VEGFR-1.
Healing of skin incisions in PlGF-deficient mice was
significantly reduced when compared to control mice
(Carmeliet et al., 2001). This effect may be explained by
pleiotrophic effects of PlGF on multiple cell types (endothe-
lial cells, hematopoietic progenitors, macrophages, and
neutrophils), involved in all stages of vascular growth in the
adult (Autiero et al., 2003). Furthermore, a recent study
suggests expression and a functional role of epidermal
VEGFR-1 during wound repair (Wilgus et al., 2005).
However, these data are contradictory to earlier and recently
published work, which could not detect VEGF-A receptor
expression or function in epidermal cells (Kurschat et al.,
2006).
Recently, a third VEGF-A receptor, neuropilin-1 (Nrp-1),
has been identified (Soker et al., 1998). Nrp-1 was originally
Figure 3. Schematic representation of interactions between VEGF family
members and their receptors. Interactions of VEGF family members
with transmembrane and soluble VEGFR-1 and VEGFR-2.
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characterized as a semaphorin receptor that is important for
guidance of developing nerves. Nrp-1 also plays a role in
vasculogenesis as Nrp-1-null-mice are embryonic lethal and
exhibit cardiovascular defects. Interestingly, beside VEGF-B,
PlGF-2, and some VEGF-E variants, VEGF165 has been
identified as the only VEGF-A isoform binding to the Nrp-1.
The VEGF-A heparin-binding domain has been identified as
the epitope for Nrp-1 binding (Soker et al., 1998). Recent
studies have shown that endothelial Nrp-1 expression
significantly facilitates VEGFR-2-mediated mitogenic, migra-
tory, and survival signaling (Whitaker et al., 2001). This
finding suggests that Nrp-1 acts as a coreceptor that enhances
VEGF165-mediated angiogenesis. Studies by Matthies et al.
(2002) suggest a role for Nrp-1 during wound angiogenesis.
Using a murine model of dermal wound repair, this group
showed abundant Nrp-1 expression on new vasculature in
healing wounds. Mice treated with neutralizing anti-Nrp-1
antibodies exhibited a significant decrease in vascular
density, indicating a functional role for Nrp-1 during wound
angiogenesis.
PROTEOLYTIC PROCESSING OF VEGF-A ISOFORMS IN
WOUND REPAIR
In addition to mRNA-splicing, proteolytic mechanisms also
generate VEGF-A variants with different biological activites
(Houck et al., 1992; Keyt et al., 1996b; Plouet et al., 1997).
This observation suggests that the proteolytic microenviron-
ment should be considered as a critical determinant
controlling VEGF-A-mediated activities. Initial evidence
supporting the hypothesis that VEGF-A proteolytic processing
regulates its activity were derived from studies analyzing the
activity of the VEGF189 isoform (Plouet et al., 1997).
Whereas native VEGF189 binds to VEGFR-1 but not
VEGFR-2, maturation of native VEGF189 by urokinase
(uPA) within the exon 6-encoded sequence resulted in its
VEGFR-2 binding and exerted a mitogenic effect on
endothelial cells. Whether VEGF189, in particular its uPA-
mediated activation, plays a role in vivo has not been
analyzed so far.
We and other investigators demonstrated the sensitivity of
VEGF165 protein to serine proteases, in particular plasmin
(Houck et al., 1992; Keyt et al., 1996b; Lauer et al., 2000,
2002). Plasmin digestion of VEGF165 yields two fragments:
an amino-terminal homodimer (VEGF1–110) containing
VEGF receptor binding determinants and a carboxyl-terminal
polypeptide comprising the heparin-binding domain
(VEGF111–165) (Keyt et al., 1996b; Lauer et al., 2000,
2002) (Figure 4). Whereas the heparin-binding affinity of the
complete VEGF165 protein and the VEGF111–165 cleavage
product were nearly equivalent, no heparin binding was
observed for the VEGF1–110 cleavage product (Keyt et al.,
1996b), indicating that the heparin-binding function of
VEGF165 is completely mediated by the carboxyl-terminal
domain. Loss of the carboxyl-terminal polypeptide through
plasmin digestion significantly reduces VEGF165 mitogenic
activity on HUVE cells (Keyt et al., 1996b; Lauer et al, 2002),
supporting the crucial significance of the heparin-binding
domain for VEGF-A function. So far, little is known about the
prevalence and biological significance of proteolytic diges-
tion of VEGF-A, in particular in the in vivo situation.
Recently, we provided evidence for the biological
significance of VEGF165 proteolytic processing in wound
healing. Comprehensive morphological and functional data
indicate that endothelial cell function and angiogenesis is
significantly disturbed in human chronic non-healing wounds
(Luetolf et al., 1993; Lauer et al., 2000). We investigated the
hypothesis whether there exists a causative link between
impaired angiogenesis and decreased VEGF-A activity in
chronic non-healing wounds. To test this hypothesis, we
analyzed VEGF-A expression and protein integrity in chronic
non-healing wounds. VEGF-A mRNA and protein expression
was highly upregulated in non-healing wounds, and levels
were comparable to normal healing wounds (Lauer et al.,
2000). Thus, these data prompted us to focus on the
degradation pathway of VEGF165 protein. Our data demon-
strated that in contrast to healing wounds, VEGF165 protein
is a target of proteolytic processing in chronic non-healing
wounds. SDS-PAGE analysis and protease inhibitor studies
strongly indicated that serine proteases, in particular plasmin,
are involved in VEGF165 processing in the context of the
chronic wound environment. In contrast, inhibitors of matrix
metalloproteinases (MMP) (EDTA, phenanthroline), of cystein
proteinases (elastinal, leupeptin, E-64, TLCK, antipain), and
of acidic proteases (pepstatin) had no effect on VEGF165
degradation in wound fluid collected from non-healing
wounds.
To further investigate the biological consequence of
plasmin-mediated VEGF165 cleavage, we identified the
plasmin cleavage site in the VEGF165 molecule (Figure 4).
Plasmin digestion of VEGF165 yielded two fragments: an
amino-terminal homodimer (VEGF1–110), which was resis-
tant to further cleavage, and a carboxyl-terminal polypeptide
(VEGF111–165) (Keyt, 1996b; Lauer et al., 2000, 2002).
Figure 4. Protease cleavage sites of VEGF-A. Plasmin or MMPs cleave
(a) human VEGF165 and (c) murine VEGF164 at indicated sites; the most
N-terminal-proximal cleavage sites are presented; plasmin digestion of
VEGF165 yields two fragments: an amino-terminal homodimer (VEGF1–110)
and a carboxyl-terminal polypeptide (VEGF111–165); (b) site-directed
mutagenesis was used to generate a plasmin-resistant VEGF165 mutant;
substitution of alanine 111 with proline 111 resulted in plasmin resistance.
Letters in italics indicate differences in the human and the murine VEGF
amino-acid sequence.
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Plasmin digestion reduced significantly the mitogenic activity
on endothelial cells (Keyt et al., 1996b; Lauer et al., 2002). By
the introduction of amino-acid alterations at the plasmin-
sensitive cleavage site Arg110/Ala111, we generated plas-
min-resistant VEGF165 mutants. Substitutions at either site
resulted in VEGF165 products that, while maintaining
growth-promoting properties, were fully plasmin-resistant.
Interestingly, a plasmin-resistant VEGF165 mutant (Ala111-
Pro111) (VEGF165A111P) showed significantly increased
stability when incubated in wound fluid derived from non-
healing wounds (Lauer et al., 2002). Taken together, our data
demonstrated that in the highly proteolytic environment of
human non-healing skin ulcers, VEGF165 degradation is
increased as compared to normal-healing wounds and VEGF-
A processing can be partially rescued by inactivation of the
plasmin-sensitive cleavage site Arg110/Ala111. Furthermore,
our data propose that reduced VEGF165 availability at the
wound site may contribute to impaired healing.
Recently, Lee et al. (2005) described additional MMP
cleavage sites in the VEGF-A protein. This group identified
MMP-3, -7, -9, and -19, which efficiently cleaved the murine
VEGF164 isoform; MMP-1 and -16 were less effectively.
MMP cleavage appeared to occur in sequential steps at
residues 135, 120, and finally at residue 113 (Figure 4).
Similar to plasmin-mediated digestion, also for MMP
cleavage the most N-terminal-proximal cleavage site resulted
in dissociation of the VEGF165/164 heparin-binding motif.
Overall, these studies support the idea that proteolytic
processing of VEGF-A is a crucial event in controlling VEGF-
A activity. These findings reveal a novel aspect in the
regulation of extracellular VEGF-A that holds significance for
angiogenesis. Although MMPs are highly involved in tissue
repair, the role of MMP-mediated processing of VEGF-A in
wound healing is currently unclear. Keyt et al. (1996b)
reported that collagenase (MMP-1), an MMP intimately
involved in wound repair, does not cleave human VEGF165.
Data from our group demonstrated that VEGF165 protein
stability in chronic wound fluid was not influenced by the
classical MMP inhibitor ethylenediaminetetraacetic acid,
proposing that in chronic wounds MMP-mediated cleavage
of VEGF165 is not the primarily proteolytic pathway (Lauer
et al., 2000).
PLASMIN RESISTANCE OF VEGF165 IMPROVES WOUND
ANGIOGENESIS
In order to further characterize the biological relevance of the
protease sensitivity of VEGF165 in vivo, in particular during
cutaneous repair, in a recent study we investigated the
stability and activity of locally applied VEGF165-wild type
(VEGF165-Wt) or a VEGF165 mutant resistant to plasmin
proteolysis (VEGF165A111P) in a genetic mouse model of
impaired healing (db/db mouse) (Roth et al., 2006). These
experiments provided the first in vivo data indicating that
plasmin-catalyzed cleavage is critical to regulate VEGF165-
mediated angiogenesis. We chose the particle-mediated gene
transfer technology, a physical means of gene delivery, to
overexpress VEGF165 variants at the wound site. Histological
and functional data indicated that the improved healing
response following VEGF165-Wt application was based on
the induction of a highly vascularized granulation tissue as
well as an accelerated re-epithelialization process. Wounds
transfected with the cDNA coding for VEGF165A111P
provoked an early granulation tissue formation, which in
regard to the vessel density and cellular composition was
similar to that induced by the wild-type molecule. However,
vessel size was significantly increased in mutant versus wild-
type-treated wounds 8 and 12 days following wounding.
Nevertheless, differences in vessel size did not affect wound
closure rate, which was similar in VEGF165-Wt- and
VEGF165A111P-transfected wounds. However, we found
significant differences regarding vessel regression in
VEGF165-Wt- and mutant-transfected wounds during later
stages in the repair process. Whereas in wild-type-transfected
wounds capillary density resolved rapidly upon completion
of wound reepithelialization, VEGF165A111P-transfected
wounds were characterized by a significant delayed involu-
tion of capillary density following wound closure. This
finding was consistent with a delayed and decreased number
of apoptotic endothelial cells in VEGF165A111P-transfected
wounds when compared to VEGF165-Wt-transfected
wounds, and it suggested an increased stability of vascular
structures in VEGF165-mutant versus VEGF165-Wt-treated
wounds.
VEGF-A is a critical survival factor for vascular endothe-
lium, in particular for immature vessels (Alon et al., 1995;
Holash et al., 1999; Dor et al., 2002). The decreased
endothelial cell apoptosis observed in mutant-treated wounds
may therefore have resulted from an increased stability and
prolonged local activity of the VEGF165 mutant. This
assumption was supported by Western blot analysis and
CD31/TUNEL analysis, which demonstrated increased stabi-
lity and activity of the VEGF165 mutant within a highly
proteolytic wound environment. In addition, our data
indicated that capillaries induced by the VEGF mutant were
characterized by an increased coating of perivascular cells.
VEGF165 is chemotactic for pericytes, and in various models
of angiogenic remodeling, ectopic application of VEGF-A has
been shown to accelerate pericyte coverage of newly formed
blood vessels, which ultimately increased vessel maturation
(Alon et al., 1995; Benjamin et al., 1998; Grosskreutz et al.,
1999). Therefore, the prolonged vessel persistence in
VEGF165A111P-transfected wounds might result from a
combination of prolonged local VEGF165 mutant activity
and increased pericyte coating.
Different structural–functional properties of the VEGF165
mutant and the wild-type protein could account for the
prolonged and enhanced activity of the mutant. We and
others have demonstrated that plasmin-catalyzed cleavage of
VEGF165 results in loss of its heparin-binding domain (Keyt
et al., 1996b; Lauer et al., 2000, 2002), which is crucially
involved in diverse biochemical and functional properties
(Park et al., 1993; Ortega et al., 1998; Soker et al., 1998;
Carmeliet et al., 1999; Dor et al., 2002; Ruhrberg et al., 2002;
Hutchings et al., 2003). Inactivation of the plasmin cleavage
site should lead to the preservation/integrity of the heparin-
binding domain in the VEGF165 molecule, which enhances
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VEGF receptor affinity and/or extracellular matrix interac-
tions. As outlined above, the VEGF-A heparin-binding
domain has been identified as the epitope for Nrp-1 binding
(Soker et al., 1998). Although endothelial VEGF-A signaling
described to date is largely mediated via VEGFR-1 and/or -2,
its mitogenic, migratory, and survival signaling can be
significantly facilitated by signaling through the membrane
bound coreceptor Nrp-1 (Whitaker et al., 2001). In addition,
the heparin-binding domain of VEGF-A isoforms is crucial for
determining its binding to extracellular matrix molecules
(Park et al., 1993; Ortega et al., 1998). Recent data have
demonstrated that the angiogenic potential of matrix-asso-
ciated isoforms is superior to soluble isoforms (Zisch et al.,
2003). Overall, effects mediated by the heparin-binding
domain may act separately and/or in concert to enhance and
prolong the activity of the plasmin-resistant VEGF165
molecule in the db/db wound environment. Our present
data provided experimental evidence that a plasmin-resistant
VEGF165 variant exerts increased stability in the highly
proteolytic environment of an impaired healing wound with
significant consequences to blood vessel persistence. Future
studies will have to investigate whether extracellular proces-
sing of VEGF165 is a frequent regulatory event in other
physiological or pathological situations of angiogenesis than
tissue repair, such as inflammation and cancer.
Lee et al. (2005) analyzed the biological impact of MMP
processing of VEGF-A in vitro and in vivo tumor models.
Carcinoma cells were transfected with different VEGF-A
variants and injected subcutaneously into a mouse model.
Interestingly, tumors that expressed the MMP-cleaved VEGF
fragment VEGF1–113 grew poorly and showed capillary
dilation of existing vessels. In contrast, tumors expressing the
MMP-resistant VEGF-A variant displayed faster growth
kinetics, and the vasculature was characterized by increased
capillary density with multiple and frequent branch points.
Similar to the enhanced angiogenic response of the plasmin-
resistant VEGF165 mutant during wound repair, altered
structural–functional properties of MMP-resistant VEGF164
might account for the accelerated tumorangiogenesis and
tumor growth observed.
Overall, these studies provide substantial evidence that
VEGF-A proteolysis occurs in vivo and might add an
additional control for VEGF-A-mediated processes. Different
structural–functional properties might account for the altered
VEGF activities of processed VEGF-A. Present studies suggest
that in particular loss of the heparin-binding domain might
result in VEGF-A fragments with altered functions. Rendering
the VEGF-A molecule resistant to proteolytic cleavage might
increase the portion of matrix-bound VEGF-A molecules,
which are more efficient in supporting a more functional
angiogenic response than soluble VEGF-A.
SOLUBLE VEGFR-1: A MEDIATOR IN TISSUE REPAIR
Besides analyzing VEGF-A processing, we were interested to
identify potential inhibitors of VEGF-A-mediated actions in
the microenvironment of non-healing wounds. So far, soluble
VEGFR-1 (sVEGFR-1), a splice variant of the membrane-
bound VEGFR-1, is considered the only naturally occurring
specific inhibitor for VEGF-A. In vitro analysis demonstrated
that sVEGFR-1 is a strong and specific inhibitor of VEGF-A-
mediated actions, and in vivo studies proved that the
recombinant secreted form of the extracellular region of
VEGFR-1 is a potent inhibitor of angiogenesis (Kendall and
Thomas, 1993; Aiello et al., 1995; Miotla et al., 2000; Mori
et al., 2000). Potentially, sVEGFR-1 functions as an inert
decoy receptor by binding VEGF-A and thereby regulating
the availability of VEGF-related ligands for the activation of
VEGFR-2 (Flk-1/KDR), the VEGF receptor principally in-
volved in VEGF signaling (Kendall and Thomas, 1993;
Barleon et al., 1997; Hiratsuka et al., 1998). Besides VEGF-
A, VEGFR-1 binds the VEGF-related proteins PIGF and VEGF-
B, however with much lower affinity (Kendall and Thomas,
1993; Hornig et al., 2000; Shibuya, 2001). Although the
precise function of PIGF and VEGF-B during cutaneous
wound repair is presently unknown, recent data indicate that
membrane-bound VEGFR-1 might be a critical signaling
receptor for PIGF during cutaneous tissue repair (Failla et al.,
2000; Carmeliet et al., 2001). Expression of sVEGFR-1 has
been described in a variety of primary human endothelial
cells, in various cancer tissues, and different biological fluids
(Kendall and Thomas, 1993; Barleon et al., 1997, 2001;
Banks et al., 1998; Hornig et al., 1999, 2000; Vuorela et al.,
2000; Tor et al., 2002). The significance of naturally
occurring sVEGFR-1 is unclear at this time.
In a recent study, we investigated the hypothesis whether
sVEGFR-1 plays a role during cutaneous wound repair and
we evaluated the expression of sVEGFR-1 in normal healing
and chronic non-healing cutaneous wounds (Eming et al.,
2004). ELISA and Western blot analysis revealed that
sVEGFR-1 concentration in wound fluid obtained from
chronic non-healing wounds was significantly increased over
levels in wound fluid obtained from healing wounds. To
assess the heterogeneity of sVEGFR-1 concentrations among
different wound fluid samples, particularly among chronic
wound fluid samples, we investigated the kinetics of sVEGFR-
1 release at different stages during the healing process.
Progression in wound healing was evaluated by assessing
granulation tissue formation and re-epithelialization by
wound tracings at indicated time points. sVEGFR-1 levels
quantified in wound fluid collected from normal healing
wounds were low at initial postoperative days, similar to
serum levels, increased during granulation tissue formation
up to a maximum and decreased with wound closure. During
a 2 month follow-up in our clinic, some of the chronic
wounds transformed from a non-healing in a healing state,
characterized by granulation tissue formation and finally
wound closure. In these patients, induction of granulation
tissue formation and wound closure was associated with a
decrease in sVEGFR-1 concentrations. The positive correla-
tion between healing progression and sVEGFR-1 decline was
statistically significant (r¼ 0.92, Po0.0005). In contrast,
sVEGFR-1 levels in chronic wounds, which did not develop
granulation tissue and did not diminish in wound size over a
period of 2 months, remained high. Interestingly, the kinetics
of sVEGFR-1 secretion in normal healing wounds resembled
those described for VEGF-A/PIGF expression during normal
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wound repair, indicating a temporal correlation of sVEGFR-1
and VEGF ligand expression during wound angiogenesis
(Nissen et al., 1998; Failla et al., 2000; Carmeliet et al.,
2001). This observation supported the idea that during
physiological angiogenesis, sVEGFR-1 may control a local
overshooting response of the increasing VEGF-related
ligands. In contrast, induction of sVEGFR-1 expression to
non-physiological levels, as measured in chronic non-healing
wounds, indicate a disturbance of the VEGF ligand/sVEGFR-1
balance; potentially, this dysregulation may attenuate vessel
growth during granulation tissue formation and hence impair
wound closure.
In summary, our report revealed the expression of
sVEGFR-1 during different stages of healing, suggesting a
function of sVEGFR-1 during tissue repair. Whether increased
sVEGFR-1 levels in non-healing wounds interfere with the
activities of VEGF-related ligands and potentially reduce
angiogenesis remains to be investigated in further studies.
However, our results lead to the intriguing hypothesis as to
whether the sVEGFR-1 level detected in wound fluid can be
of prognostic value for differentiating an effective or impaired
wound healing response. An indicator for healing would be
of great value to assess disease severity and progression of the
chronic wound, and might serve as predictive indicator for
the efficacy of a certain therapy regime.
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CONCLUSION
In recent studies, we and others provided evidence that
proteolytic processing of VEGF-A might be an important
event controlling VEGF-A activity in tissue repair, inflamma-
tion, and cancerogenesis. Indeed, our data indicate that
increased proteolysis of VEGF-A in the highly proteolytic
microenvironment of the chronic wound leads to VEGF-A
inactivation and reduced VEGF165 availability at the wound
site, which might contribute to an impaired healing response.
Besides VEGF-A proteolysis, our studies on sVEGFR-1 suggest
an additional mechanism, which compromises VEGF-A-
mediated angiogenesis in chronic non-healing wounds.
These observations might have clinical impact. In the highly
proteolytic environment of the non-healing human wound, a
protease-resistant VEGF165 mutant might be more effective
in stimulating wound angiogenesis and to improve wound
closure. Further topical applied VEGF-A protein may shift the
increased and antiangiogenic sVEGFR-1/VEGF-A balance of
the non-healing wound to a proangiogenic response that
favors repair. However, in tumor development, protease
inhibition might increase the portion of matrix-bound VEGF-
A, which could promote tumor growth. These observations
are interesting and merit future studies, which analyze
whether pathways of VEGF-A proteolysis might be different
and potentially functional relevant in diverse disease states
and organs.
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